Glucose-dependent signaling
It increases insulin secretion and reduces inappropriate glucagon secretion when blood glucose is elevated.
P—02 • Clinically established profile
Semaglutide
A concise educational overview of a clinically established GLP-1 receptor agonist used in metabolic medicine and studied across cardiovascular, kidney, and liver health.
Name
Semaglutide
Available in multiple indication-specific prescription formulations
- Scientific classification
- Long-acting, acylated glucagon-like peptide-1 analogue and GLP-1 receptor agonist
- Library family
- Metabolic
- Research status
- Clinically established with continuing clinical research
- Regulatory status
- FDA approved in specific formulations for indication-dependent uses
Compound overview
A long-acting GLP-1 analogue with established clinical applications.
Semaglutide is a synthetic peptide modeled after the naturally occurring GLP-1 hormone. Structural modifications help it resist enzymatic breakdown and remain active longer than native GLP-1.
Different FDA-approved semaglutide products have different formulations, doses, and approved purposes. Approval does not extend automatically to every semaglutide formulation or compounded product.
Mechanism under study
Long-acting GLP-1 receptor signaling
Semaglutide activates the GLP-1 receptor and influences glucose-dependent pancreatic signaling, appetite and energy intake, and gastrointestinal function.
Appetite and energy intake
GLP-1 receptor signaling in the central nervous system can reduce appetite and influence caloric intake.
Gastric emptying
Semaglutide can slow gastric emptying, particularly following administration, which contributes to its metabolic effects.
The magnitude and clinical meaning of these effects depend on the formulation, approved indication, studied population, and individual circumstances.
Current research areas
Questions under investigation
- Glycemic regulation in type 2 diabetes
- Obesity and long-term weight management
- Cardiovascular outcomes
- Chronic kidney disease associated with type 2 diabetes
- Metabolic liver disease and related complications
Evidence summary
Evidence-supported clinical outcomes
- Glycemic control: Approved semaglutide formulations improve blood-glucose control in adults with type 2 diabetes.
- Weight management: Clinical trials demonstrate substantial average weight reduction in defined populations with overweight or obesity.
- Cardiovascular risk reduction: Certain formulations reduce the risk of cardiovascular death, nonfatal heart attack, or nonfatal stroke in approved populations.
- Kidney outcomes: Semaglutide has reduced major kidney-disease outcomes in adults with type 2 diabetes and chronic kidney disease.
- Metabolic liver health: A semaglutide formulation has received accelerated approval for certain adults with noncirrhotic metabolic dysfunction-associated steatohepatitis and moderate-to-advanced fibrosis.
Benefits depend upon the specific formulation, approved indication, study population, and individual clinical circumstances.
Educational notice
Education, not usage guidance.
This profile is provided for scientific education only. It is not medical advice, a treatment recommendation, dosing information, or instructions for use. Approved semaglutide products require evaluation and prescribing by a qualified healthcare professional.
Key scientific referencesComing soon
A curated primary-source reference list will be added during the next educational expansion.